 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- LX-039 / WuXi AppTec, Luoxin Pharma
Results from a first-in-human phase Ia/b study of LX-039, an oral selective estrogen receptor (ER) degrader (SERD), in postmenopausal patients with ER+, HER2- advanced breast cancer (ABC) () - Jul 27, 2023 - Abstract #ESMO2023ESMO_2007;
P1
Conclusions LX-039 was well tolerated with preliminary anti-tumor activity in ER+, HER2- ABC. RP2D was determined at 600 mg QD and a phase II trial is being planned.
- || LX-039 / WuXi AppTec, Luoxin Pharma
Trial completion, Enrollment change, Trial completion date, Metastases: A Phase I Study of LX-039 Tablets (clinicaltrials.gov) - May 1, 2023
P1, N=44, Completed, Sponsor: Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
RP2D was determined at 600 mg QD and a phase II trial is being planned. Enrolling by invitation --> Completed | N=68 --> 44 | Trial completion date: Jul 2023 --> Feb 2023
- | LX-039 / WuXi AppTec
Preclinical, Journal: Discovery and preclinical profile of LX-039, a novel indole-based oral selective estrogen receptor degrader (SERD). (Pubmed Central) - May 4, 2022
P1
We report herein its profound anti-tumor activity, desirable ER antagonistic characteristics combined with favorable pharmacokinetic and preliminary safety properties. LX-039 is currently in clinical trial (NCT04097756).
- ||| LX-039 / WuXi AppTec, Luoxin Pharma
Enrollment open, Trial initiation date, Metastases: A Phase I Study of LX-039 Tablets (clinicaltrials.gov) - Feb 9, 2020
P1, N=68, Enrolling by invitation, Sponsor: Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
LX-039 is currently in clinical trial (NCT04097756). Not yet recruiting --> Enrolling by invitation | Initiation date: Sep 2019 --> Jan 2020
- | LX-039 / WuXi AppTec, Luoxin Pharma
New P1 trial, Metastases: A Phase I Study of LX-039 Tablets (clinicaltrials.gov) - Sep 19, 2019
P1, N=68, Not yet recruiting, Sponsor: Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.